PRINZIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRINZIDE (PRINZIDE).
PRINZIDE is a combination of lisinopril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
| Metabolism | Lisinopril: minimally metabolized; excreted unchanged in urine. Hydrochlorothiazide: not extensively metabolized; eliminated mainly by renal tubular secretion. |
| Excretion | Lisinopril is excreted unchanged in urine (100% renal elimination); hydrochlorothiazide is excreted 95% renally as unchanged drug and 5% via bile. |
| Half-life | Lisinopril: terminal half-life 12 hours (effective half-life 30 hours due to prolonged ACE binding). Hydrochlorothiazide: terminal half-life 6-15 hours (biphasic, initial phase 2-4 h, terminal phase 6-15 h) with prolonged terminal phase in renal impairment. |
| Protein binding | Lisinopril: 25% bound to plasma proteins. Hydrochlorothiazide: 40-68% bound, primarily to albumin. |
| Volume of Distribution | Lisinopril: Vd ~2 L/kg (extensive tissue distribution). Hydrochlorothiazide: Vd ~0.8 L/kg (distributes into extracellular fluid; crosses placenta). |
| Bioavailability | Lisinopril: oral bioavailability 25% (not affected by food). Hydrochlorothiazide: oral bioavailability 65-75% (increases with food due to enhanced absorption). |
| Onset of Action | Oral: antihypertensive effect occurs within 1 hour for lisinopril, peak at 4-6 hours; diuretic effect for hydrochlorothiazide begins at 2 hours, peak at 4-6 hours. |
| Duration of Action | Lisinopril: 24 hours (once-daily dosing). Hydrochlorothiazide: 6-12 hours (antihypertensive effect may persist up to 24 hours with chronic use). |
| Molecular Weight | Lisinopril: 405.49 Da; Hydrochlorothiazide: 297.74 Da |
Oral, 1-2 tablets daily; each tablet contains 25 mg hydrochlorothiazide and 5 mg lisinopril. Adjust based on blood pressure response; maximum daily dose: 2 tablets.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-80 mL/min: initial dose 1 tablet daily; CrCl 10-29 mL/min: initial dose 0.5 tablet daily; CrCl <10 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce initial dose by 50%; Child-Pugh Class C: contraindicated. |
| Pediatric use | Not recommended for children under 18 years due to lack of safety and efficacy data. |
| Geriatric use | Start with lower initial dose (0.5 tablet daily) due to age-related decline in renal function and increased sensitivity; monitor electrolytes and renal function closely. |
| 1st trimester | Contraindicated due to increased risk of congenital malformations, particularly cardiovascular and central nervous system defects, from first-trimester exposure to ACE inhibitors. |
| 2nd trimester | Contraindicated: Risk of fetal oligohydramnios, renal dysfunction, and oligohydramnios sequence, with potential for fetal hypotension and anuria. |
| 3rd trimester | Contraindicated: Same risks as second trimester, including oligohydramnios, fetal renal impairment, and neonatal hypotension. |
Clinical note
Comprehensive clinical and safety monograph for PRINZIDE (PRINZIDE).
| Placental transfer | Both lisinopril and hydrochlorothiazide cross the placenta. Lisinopril is an ACE inhibitor that crosses the placental barrier, and hydrochlorothiazide also crosses. Fetal exposure is confirmed through adverse fetal and neonatal outcomes. |
| Breastfeeding | Hydrochlorothiazide is excreted into breast milk in small amounts, while lisinopril is excreted in trace amounts not expected to cause adverse effects in nursing infants. However, use with caution due to potential for hypotension and renal effects in preterm or infants with impaired renal function. Monitor infant for signs of hypotension. |
■ FDA Black Box Warning
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause morbidity and death in the developing fetus. Discontinue as soon as possible when pregnancy is detected.
| Serious Effects |
History of angioedema related to previous ACE inhibitor therapyHereditary or idiopathic angioedemaAnuriaHypersensitivity to lisinopril, hydrochlorothiazide, or sulfonamide-derived drugsConcomitant use with aliskiren in patients with diabetesPregnancy (especially second and third trimesters)
| Precautions | Angioedema (risk increased in black patients, prior history), Hypotension (especially in volume-depleted patients), Renal impairment (monitor renal function), Electrolyte disturbances (hyperkalemia, hyponatremia, hypomagnesemia), Acute angle-closure glaucoma (sulfonamide-related) |
| Food/Dietary | High-potassium foods (e.g., bananas, oranges, tomatoes, spinach, salt substitutes) should be consumed consistently and not in large excess; lithium carbonate may increase lithium levels; avoid dofetilide due to increased risk of torsades de pointes. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations, particularly cardiovascular and central nervous system defects (based on ACE inhibitor class). Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria; risk of neonatal renal failure and death. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. |
| Fetal Monitoring | Maternal: Blood pressure, renal function (serum creatinine, BUN), serum electrolytes (especially potassium), and urine output. Fetal/neonatal: Ultrasound for oligohydramnios, fetal growth, and renal function; neonatal monitoring for hypotension, hyperkalemia, and renal insufficiency. |
| Fertility Effects | Animal studies with lisinopril/hydrochlorothiazide have shown no significant effects on fertility. In humans, ACE inhibitors may theoretically affect angiotensin II-mediated reproductive processes, but data are limited. No specific adverse fertility effects reported. |
| Clinical Pearls | Monitor serum potassium and renal function at baseline and periodically, especially in elderly, diabetic, or volume-depleted patients., Initiate at 12.5 mg hydrochlorothiazide / 50 mg lisinopril once daily, titrate to maximum 25 mg/50 mg once daily., Use caution in patients with bilateral renal artery stenosis; may cause acute renal failure., Concomitant use with potassium supplements, potassium-sparing diuretics, or salt substitutes may cause hyperkalemia., Consider dose reduction in moderate hepatic impairment; lisinopril is a prodrug requiring hepatic activation. |
| Patient Advice | Take exactly as prescribed, usually once daily, with or without food. · May cause dizziness or lightheadedness; avoid driving until you know how this medication affects you. · Do not stop abruptly; can cause dangerous blood pressure spikes. · Report persistent cough, swelling of lips/tongue, hyperkalemia symptoms (muscle weakness, irregular heartbeat), or signs of angioedema. · Limit alcohol, avoid salt substitutes high in potassium, and maintain adequate hydration. · Before surgery, inform your surgeon you are taking this medication. |